Inflammatory bowel disease

Primary Care - Clinics in Office Practice

Volumn 38, Issue 3, 2011, Pages 415-432

  Walsh, Anne ^a,b,c   Mabee, John ^a,b   Trivedi, Kashyap ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Hertz and Associates in Gastroenterology   (United States)

Author keywords

Crohn disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BACTERIUM ANTIBODY; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTANEMA; CORTICOSTEROID; CYCLOSPORIN; FLAGELLIN; FUNGUS ANTIBODY; GAMMA INTERFERON; HYDROCORTISONE; HYDROCORTISONE ACETATE PLUS PRAMOCAINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; NATALIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; AGRANULOCYTOSIS; ALLERGIC PNEUMONITIS; ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; BONE MARROW SUPPRESSION; CANCER SCREENING; CAPSULE ENDOSCOPY; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC IMAGING; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENTERITIS; ESOPHAGOGASTRODUODENOSCOPY; GENETIC SCREENING; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INTERSTITIAL NEPHRITIS; INTESTINE BIOPSY; INTESTINE RADIOGRAPHY; LABORATORY TEST; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER TOXICITY; MALAISE; MALE INFERTILITY; MOOD DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUTRITIONAL DEFICIENCY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATHOPHYSIOLOGY; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PYODERMA GANGRENOSUM; RASH; REVIEW; SEIZURE; SIDE EFFECT; SIGMOIDOSCOPY; THROMBOCYTOPENIA; ULCERATIVE COLITIS; UVEITIS; VACCINATION; VOMITING; WEIGHT GAIN; WOMEN'S HEALTH;

BONE DISEASES, METABOLIC; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIFE STYLE; MALNUTRITION; VACCINES; WOMEN'S HEALTH;

EID: 80052344199     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.06.001     Document Type: Review

References (55)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126(6):1504-1517.
2. U.S. Census Bureau. U.S. POPClock projection. Available at: Accessed June 15, 2010. http://www.census.gov/population/www/popclockus.html.
3. Statistics Canada. Canada's population clock. Available at: Accessed June 15, 2010. http://www.statcan.gc.ca/pub/82-003-x/pop/pop-h-clock-eng.htm.
4. Hou J.K., El-Serag H., Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009, 104(8):2100-2109.
5. Lynch H.T., Brand R.E., Locker G.Y. Inflammatory bowel disease in Ashkenazi Jews: implications for familial colorectal cancer. Fam Cancer 2004, 3(3-4):229-232.
6. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5(12):1424-1429.
7. Sonnenberg A., McCarty D.J., Jacobsen S.J. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991, 100(1):143-149.
8. Mahid S.S., Minor K.S., Soto R.E., et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006, 81(11):1462-1471.
9. Klement E., Cohen R.V., Boxman J., et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004, 80(5):1342-1352.
10. Andersson R.E., Olaison G., Tysk C., et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001, 344(11):808-814.
11. Cornish J.A., Tan E., Simillis C., et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008, 103(9):2394-2400.
12. Guslandi M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?. World J Gastroenterol 2006, 12(10):1509-1510.
13. Kurina L.M., Goldacre M.J., Yeates D., et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001, 55(10):716-720.
14. Orholm M., Binder V., Sørensen T.I.A., et al. Concordance of inflammatory bowel disease among Danish twins. Scand J Gastroenterol 2000, 35(10):1075-1081.
15. Hakonarson H., Grant S.F.A. Genome-wide association studies in type 1 diabetes, inflammatory bowel disease and other immune-mediated disorders. Semin Immunol 2009, 21(6):355-362.
16. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010, 45(1):9.
17. Abraham C., Cho J.H. Mechanisms of disease: inflammatory bowel disease. N Engl J Med 2009, 361(21):2066-2078.
18. Louis E., Belaiche J., Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease?. World J Gastroenterol 2010, 16(21):2600-2603.
19. Yakut M., Ustun Y., Kabacam G., et al. Serum vitamin B12 and folate status in patients with inflammatory bowel disease. Eur J Intern Med 2010, 21:320-323.
20. Sidhu R., Wilson P., Wright A., et al. Faecal lactoferrin, a novel test to differentiate between the irritable and inflamed bowel?. Aliment Pharmacol Ther 2010, 31:1365-1370.
21. Jorgensen S.P., Agnholt J., Glerup H., et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo controlled study. Aliment Pharmacol Ther 2010, 32:377-383.
22. Benor S., Russell G., Silver M., et al. Shortcomings of the inflammatory bowel disease serology 7 panel. Pediatrics 2010, 125(6):1230-1236.
23. Dubinsky M. Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16(21):2604-2608.
24. Allez M., Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16:2626-2632.
25. Petruzziello C., Onali S., Calabrese E., et al. Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World J Gastroenterol 2010, 16:3299-3304.
26. Messaris E., Nikolaos C., Grand D., et al. Role of magnetic resonance enterography in the management of Crohn's disease. Arch Surg 2010, 145:471-475.
27. Colombel J.F., Watson A.J., Neurath M.F. The 10 remaining mysteries of inflammatory bowel disease. Gut 2008, 57:429-433.
28. Yamamoto T., Nakahigashi M., Saniabadi A.R. Review article: diet and inflammatory bowel disease-epidemiology and treatment. Aliment Pharmacol Ther 2009, 30:99-112.
29. Sakamoto N., Kono S., Wakai K., et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005, 11:154-163.
30. Akobeng A.K., Thomas A.G. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007, 3. CD005984. Accessed July 31, 2010.
31. Turner D., Zlotkin S.H., Shah P.S., et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 1. CD006320. Accessed July 31, 2010.
32. Goh J., O'Morain C.A. Review article: nutrition and inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:307-320.
33. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
34. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2. CD000543. Accessed July 31, 2010.
35. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2. CD000544. Accessed July 31, 2010.
36. Bergman R., Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006, 23:841-855.
37. Sparrow M., Irving P., Baidoo L., et al. Current controversies in Crohn's disease: a roundtable discussion of the BRIDGe Group. Gastroenterol Hepatol 2008, 4:713-720.
38. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
39. Roses R.E., Rombeau J.L. Recent trends in the surgical management of inflammatory bowel disease. World J Gastroenterol 2008, 14:408-412.
40. Benchimol E.I., Seow C.H., Otley A.R., et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 1. CD002913. Accessed July 31, 2010.
41. D'Haens G., Rutgeerts P. Immunosuppression-associated lymphoma in IBD. Lancet 2009, 374:1572-1573.
42. Rutgeerts P., Vermeire S., Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-1197.
43. Lakatos P.L., Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Curr Drug Targets 2010, 11:179-186.
44. Mackey A.C., Green L., Leptak C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48:386-388.
45. Prantera C., Scribano M.L. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 2009, 25:329-333.
46. Travis S.P., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006, 55(Suppl 1):i16-i35.
47. Herbrecht R., Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005, 40:1635-1637.
48. Hwang J.M., Varma M.G. Surgery for inflammatory bowel disease. World J Gastroenterol 2008, 14:2678-2690.
49. Ali T., Lam D., Bronze M.S., et al. Osteoporosis in inflammatory bowel disease. Am J Med 2009, 122:599-604.
50. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
51. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
52. Mpofu C., Watson A.J., Rhodes J.M. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2004, 2. CD000279. Accessed July 31, 2010.
53. Melmed G.Y., Ippoliti A.F., Papadakis K.A., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101:1834-1840.
54. Qumseya B., Ananthakrishnan A., Skaros S., et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011, 17(1):77-83.
55. Stephansson O., Larsson H., Pederson L., et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010, 8(6):509-515.